FDA Clearance Tracker · P240040-S002
Oncomine Dx Express Test
Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Oct 15, 2025
Approved
Time to decision
75 days
Received Aug 1, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P240040-S002
- Device name
- Oncomine Dx Express Test
- Applicant
- Life Technologies Corporation
- Applicant location
- Frederick, MD
- Received
- Aug 1, 2025
- Decided
- Oct 15, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P240040
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of the non-clinical Post-Approval Study (PAS) protocol for precision and sample equivalency studies using core needle biopsy and fine needle aspirate samples (PCP0141593).
Source documents
Other decisions for Life Technologies Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260827 · Decided Oct 15, 2026 · 216 days after receipt
Device type: High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids (SBY) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.